FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149293464> ?p ?o ?g. }

• W2149293464 endingPage "1358" @default.
• W2149293464 startingPage "1353" @default.
• W2149293464 abstract "Vasculitides are classified on the basis of the type of cell involved, namely, eosinophilic vasculitides such as Churg-Strauss syndrome (CSS) and noneosinophilic vasculitides. However, knowledge on inflammatory mediators and oxidative tissue damage associated with vasculitides is insufficient.We measured the urinary concentrations of inflammatory mediators and tyrosine derivatives to assess biomarkers associated with the pathophysiology of vasculitides.Urine was collected from 9 patients with CSS during acute exacerbation and during clinical remission, 24 patients with rheumatoid arthritis in stable condition, and 8 patients with vasculitis diseases (VDs) during acute exacerbation. Leukotriene E 4 (LTE 4 ), 9alpha,11beta prostaglandin F 2 , and eosinophil-derived neurotoxin (EDN) concentrations were determined by enzyme immunoassay. 3-Bromotyrosine (BrY) and 3-chlorotyrosine (ClY) concentrations were determined by gas chromatography-mass spectrometry.The urinary LTE 4 , EDN, BrY, and ClY concentrations were significantly higher in the patients with CSS during acute exacerbation than in healthy control subjects and, except for urinary ClY concentration, significantly decreased during clinical remission. The urinary EDN and BrY concentrations were significantly higher in patients with CSS during acute exacerbation than in patients with VD during acute exacerbation. Only urinary LTE 4 concentration was significantly different between the patients with rheumatoid arthritis in stable condition and the patients with VD during acute exacerbation.Oxidative tissue damage caused by eosinophil peroxidase is a pathophysiological characteristic of eosinophil-associated diseases such as CSS. Urinary LTE 4 concentration may reflect a pathophysiological event involved in eosinophilic and noneosinophilic vasculitides. Cysteinyl-leukotriene pathways are potential therapeutic targets for small-vessel vasculitides." @default.
• W2149293464 created "2016-06-24" @default.
• W2149293464 creator A5004446959 @default.
• W2149293464 creator A5015288329 @default.
• W2149293464 creator A5019331714 @default.
• W2149293464 creator A5045338781 @default.
• W2149293464 creator A5048262782 @default.
• W2149293464 creator A5063853635 @default.
• W2149293464 creator A5075835452 @default.
• W2149293464 creator A5076559955 @default.
• W2149293464 creator A5079625263 @default.
• W2149293464 date "2004-12-01" @default.
• W2149293464 modified "2023-10-16" @default.
• W2149293464 title "Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides" @default.
• W2149293464 cites W1483091000 @default.
• W2149293464 cites W1503257987 @default.
• W2149293464 cites W1567781128 @default.
• W2149293464 cites W1680535784 @default.
• W2149293464 cites W1943694240 @default.
• W2149293464 cites W1971569966 @default.
• W2149293464 cites W1975760990 @default.
• W2149293464 cites W1976215310 @default.
• W2149293464 cites W1987316799 @default.
• W2149293464 cites W1988203407 @default.
• W2149293464 cites W1988708695 @default.
• W2149293464 cites W1989266329 @default.
• W2149293464 cites W1991469497 @default.
• W2149293464 cites W1997789323 @default.
• W2149293464 cites W1999909589 @default.
• W2149293464 cites W2017997885 @default.
• W2149293464 cites W2022357485 @default.
• W2149293464 cites W2031593366 @default.
• W2149293464 cites W2033514267 @default.
• W2149293464 cites W2035961359 @default.
• W2149293464 cites W2038284056 @default.
• W2149293464 cites W2039582264 @default.
• W2149293464 cites W2047605700 @default.
• W2149293464 cites W2051808004 @default.
• W2149293464 cites W2058357010 @default.
• W2149293464 cites W2059317915 @default.
• W2149293464 cites W2064659260 @default.
• W2149293464 cites W2067214540 @default.
• W2149293464 cites W2071170294 @default.
• W2149293464 cites W2075034126 @default.
• W2149293464 cites W2084606714 @default.
• W2149293464 cites W2087593387 @default.
• W2149293464 cites W2092522316 @default.
• W2149293464 cites W2115561143 @default.
• W2149293464 cites W2128411850 @default.
• W2149293464 cites W2150534327 @default.
• W2149293464 cites W2152348310 @default.
• W2149293464 cites W2152874793 @default.
• W2149293464 cites W2154658221 @default.
• W2149293464 cites W2162392918 @default.
• W2149293464 cites W2162725007 @default.
• W2149293464 cites W2167273192 @default.
• W2149293464 cites W2171950933 @default.
• W2149293464 cites W2264075806 @default.
• W2149293464 cites W2317186316 @default.
• W2149293464 cites W2417872743 @default.
• W2149293464 cites W4232838206 @default.
• W2149293464 doi "https://doi.org/10.1016/j.jaci.2004.09.027" @default.
• W2149293464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15577834" @default.
• W2149293464 hasPublicationYear "2004" @default.
• W2149293464 type Work @default.
• W2149293464 sameAs 2149293464 @default.
• W2149293464 citedByCount "31" @default.
• W2149293464 countsByYear W21492934642012 @default.
• W2149293464 countsByYear W21492934642013 @default.
• W2149293464 countsByYear W21492934642014 @default.
• W2149293464 countsByYear W21492934642015 @default.
• W2149293464 countsByYear W21492934642018 @default.
• W2149293464 countsByYear W21492934642019 @default.
• W2149293464 countsByYear W21492934642020 @default.
• W2149293464 countsByYear W21492934642023 @default.
• W2149293464 crossrefType "journal-article" @default.
• W2149293464 hasAuthorship W2149293464A5004446959 @default.
• W2149293464 hasAuthorship W2149293464A5015288329 @default.
• W2149293464 hasAuthorship W2149293464A5019331714 @default.
• W2149293464 hasAuthorship W2149293464A5045338781 @default.
• W2149293464 hasAuthorship W2149293464A5048262782 @default.
• W2149293464 hasAuthorship W2149293464A5063853635 @default.
• W2149293464 hasAuthorship W2149293464A5075835452 @default.
• W2149293464 hasAuthorship W2149293464A5076559955 @default.
• W2149293464 hasAuthorship W2149293464A5079625263 @default.
• W2149293464 hasConcept C10162356 @default.
• W2149293464 hasConcept C126322002 @default.
• W2149293464 hasConcept C203014093 @default.
• W2149293464 hasConcept C2776015282 @default.
• W2149293464 hasConcept C2776042228 @default.
• W2149293464 hasConcept C2777014857 @default.
• W2149293464 hasConcept C2777037409 @default.
• W2149293464 hasConcept C2777575956 @default.
• W2149293464 hasConcept C2778910314 @default.
• W2149293464 hasConcept C2779134260 @default.
• W2149293464 hasConcept C71924100 @default.
• W2149293464 hasConcept C77411442 @default.
• W2149293464 hasConcept C90924648 @default.

• next